found a high percentage of aromatase expression positivity in patients with LG-ESS, implying that aromatase inhibitors (e.g., letrozole) may play a role in the treatment of LG-ESS (25). The gene discussed is CYP19A1; the disease is endometrioid stromal sarcoma.